ACST.V · Acasti Pharma Inc

-

Please sign in to comment on ACST.V

1 Comment

Admin

3 years, 7 months ago

Acasti Pharma Inc is currently in a long term uptrend where the price is trading 12.5% above its 200 day moving average.

From a valuation standpoint, the stock is 31.5% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 698.7.

Acasti Pharma Inc's total revenue rose by inf% to $81K since the same quarter in the previous year.

Its net income has increased by 73.3% to $-3M since the same quarter in the previous year.

Finally, its free cash flow grew by 55.4% to $-4M since the same quarter in the previous year.

Based on the above factors, Acasti Pharma Inc gets an overall score of 5/5.

ISIN	CA00430K8730
Industry	Biotechnology
Sector	Healthcare
CurrencyCode	CAD
Exchange	V

Beta	1.22
Target Price	2.45
PE Ratio	None
Market Cap	26M
Dividend Yield	0.0%

ABOUT

Acasti Pharma Inc

Acasti Pharma Inc., a biopharmaceutical company, engages in the development and commercialization of pharmaceutical products for cardiovascular diseases. It is evaluating strategic partnerships for the clinical development of CaPre. The company was incorporated in 2002 and is headquartered in Laval, Canada.

ACST.V · Acasti Pharma Inc

-

Acasti Pharma Inc

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest Acasti Pharma Inc using a moving average strategy